Tue, January 28, 2025
Mon, January 27, 2025
Sun, January 26, 2025
Sat, January 25, 2025
Fri, January 24, 2025

Goldman Sachs raises AbbVie stock price target to $208

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. chs-raises-abbvie-stock-price-target-to-208.html
  Print publication without navigation Published in Stocks and Investing on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
  Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the pharmaceutical company's shares to $208.00, up from the previous target of $205.00.

Goldman Sachs has increased its price target for AbbVie Inc. to $208 from $173, maintaining a "buy" rating on the stock. This adjustment reflects optimism about AbbVie's future performance, particularly due to the potential of its new drug, Skyrizi, which is expected to drive significant revenue growth. The stock has already seen a 10% increase year-to-date, and with the new price target, Goldman Sachs analysts suggest that AbbVie could see further gains, supported by its robust pipeline and strategic market positioning.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/goldman-sachs-raises-abbvie-stock-price-target-to-208/ar-AA1xWese ]